Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Multiple sclerosis
Unexpected side effects when switching from natalizumab to a biosimilar
- Immunotherapy
Subcutaneously or intravenously?
- Work-related asthma
When the job leads to exacerbations
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- De-escalation strategies
De-escalation strategies – less is more
- Pain and autism
Hurdles to pain treatment for autistic patients
- Advanced NSCLC
MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC
- Pathophysiological mechanisms and therapeutic perspectives